Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria

Blood Cells Mol Dis. 2021 Mar:87:102528. doi: 10.1016/j.bcmd.2020.102528. Epub 2020 Dec 8.

Abstract

While red blood cells (RBCs) and granulocytes have been more studied, platelets and reticulocytes are not commonly used in paroxysmal nocturnal hemoglobinuria (PNH) flow-cytometry and less is known about susceptibility to complement-mediated destruction and effects of anti-complement therapy on these populations. We performed flow-cytometry of RBCs and granulocytes in 90 PNH patients and of platelets and reticulocytes in a subgroup (N = 36), to unveil perturbations of these populations during PNH disease course before and after anti-complement treatment. We found that platelets and reticulocytes were less sensitive to complement-mediated lysis than RBCs but not as resistant as granulocytes, as shown by mean sensitive fraction (difference in a given PNH population vs. PNH granulocyte clone size). In treated patients, reticulocytes, platelets, RBCs (with differences between type II and III) and granulocytes significantly increased post-treatment, confirming the role of PNH hematopoiesis within the context of anti-complement therapy. Moreover, we found that PNH platelet clone size reflects PNH granulocyte clone size. Finally, we established correlations between sensitive fraction of PNH cell-types and thrombosis. In sum, we applied a flow-cytometry panel for investigation of PNH peripheral blood populations' perturbations before and after eculizumab treatment to explore complement-sensitivity and kinetics of these cells during the disease course.

Keywords: Complement; GPI-AP deficiency; PNH; Platelets.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Blood Cells / cytology
  • Blood Cells / drug effects*
  • Blood Platelets / cytology
  • Blood Platelets / drug effects
  • Complement Inactivating Agents / pharmacology
  • Complement Inactivating Agents / therapeutic use*
  • Erythrocytes / cytology
  • Erythrocytes / drug effects
  • Erythroid Cells / cytology
  • Erythroid Cells / drug effects
  • Female
  • Flow Cytometry
  • Granulocytes / cytology
  • Granulocytes / drug effects
  • Hemoglobinuria, Paroxysmal / blood
  • Hemoglobinuria, Paroxysmal / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Reticulocytes / cytology
  • Reticulocytes / drug effects
  • Young Adult

Substances

  • Antibodies, Monoclonal, Humanized
  • Complement Inactivating Agents
  • eculizumab